BALTIMORE, Maryland, October 20, 2015 /PRNewswire/ --
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
In the article, analyst Rob Goldman notes that the use of encapsulation techniques to treat Type 1 diabetes (T1D) has become a viable and high profile approach in recent months, with the support and funding of the Juvenile Diabetes Research Foundation (JDRF). Interestingly, the approach designed and championed by PharmaCyte Biotech has a number of advantages over the techniques used in current, early stage human clinical trials funded in part by the JDRF.
According to Goldman, "With over $200 million in assets, the Juvenile Diabetes Research Foundation (JDRF) is the leading research organization focused on T1D research. The JDRF is helping fund what are deemed as two promising clinical trials using varied encapsulation techniques involving the implantation of cells encapsulated in a material known as alginate, a derivative of seaweed."
Goldman also noted, "The potential stumbling block with these trials is that according to most studies, over time the body's immune system attacks the alginate, impairing the ability of the cells encapsulated inside the alginate to achieve their objective. Conversely, PharmaCyte Biotech uses a cellulose-based encapsulation technology, Cell-in-a-Box[®],, which uses a bio-inert, non-toxic, biocompatible material to make pin-head sized capsules that protect the encapsulated cells from attack by the body's defense mechanisms. At the same time, the capsules provide a microenvironment that enables encapsulated cells to survive for long periods of time, which is a major advantage over other encapsulation technologies, such as those using alginate."
"As a result, PharmaCyte Biotech's Cell-in-a-Box®-based treatment system approach could not only emerge as the superior encapsulation technique used to treat T1D, but it could attract the attention of the JDRF and other major diabetes research sponsors, " commented Goldman.
Goldman also stated, "The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes, and could potentially replace them."
"With the high-profile shift toward the utilization of encapsulation techniques to treat T1D in research studies taking center stage, and with PharmaCyte Biotech's own encapsulation system/Melligen preclinical studies in the offing, the value of the Company's technology to treat this far-reaching disease is primed to receive a boost," according to Goldman.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $18,000 for investment research services that includes the publication of research reports, updates, and a series of articles.
About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at http://www.PharmaCyteBiotech.com.
Goldman Small Cap Research
Rob Goldman, Analyst
SOURCE Goldman Small Cap Research